Press
releases

Exscalate4Cov performed in Italy the most complex supercomputing experiment to identify new therapies against Sars Cov2 virus.

November 23, 2020

European and South Korean agreement signed on joint development of a COVID-19 treatment using raloxifene

November 18, 2020

EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid-19 Patients treated at Home and in Medical Facilities

October 27, 2020

Dompé Appoints New Global Biotech Head

September 21, 2020

COVID-19 - Brazilian Health Regulatory Agency (ANVISA) authorizes Dompé’s REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients

September 1, 2020

EU-supported Private-Public Consortium Exscalate4CoV : Raloxifene proposed for clinical trials after tests show it inhibits SARS-CoV-2

June 18, 2020

Dompé farmaceutici S.p.A and the Chinese Academy of Sciences collaborate on in-depth studies of over 50 molecules active against Sars-Cov-2

June 9, 2020

Dompé to Present Phase II Clinical Data for Ladarixin in New-Onset Type 1 Diabetes (T1D) at the American Diabetes Association’s Scientific Sessions

June 8, 2020

AIFA Announces Italian Authorization of Phase 2/3 Clinical Trial of Dompé's Reparixin for the Treatment of Severe Patients with COVID-19 Pneumonia

May 12, 2020

Exscalate4CoV supercomputing platform wins 3 million euro EU funding to hunt for new drugs against Coronavirus pandemic

March 6, 2020